Copyright Reports & Markets. All rights reserved.

Global Tisotumab Vedotin Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Tisotumab Vedotin Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Monoclonal Antibodies
    • 1.3.3 Polyclonal Antibodies
  • 1.4 Market Analysis by Specification
    • 1.4.1 Overview: Global Tisotumab Vedotin Consumption Value by Specification: 2021 Versus 2025 Versus 2032
    • 1.4.2 40 mg / vial
    • 1.4.3 20 mg / vial
  • 1.5 Market Analysis by Sales Channels
    • 1.5.1 Overview: Global Tisotumab Vedotin Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
    • 1.5.2 Hospital
    • 1.5.3 Retail
    • 1.5.4 Online
  • 1.6 Market Analysis by Production Technology
    • 1.6.1 Overview: Global Tisotumab Vedotin Consumption Value by Production Technology: 2021 Versus 2025 Versus 2032
    • 1.6.2 Intravenous Infusion, IV
    • 1.6.3 Ocular Prophylaxis-related Administration
  • 1.7 Market Analysis by Application
    • 1.7.1 Overview: Global Tisotumab Vedotin Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.7.2 R/M Cervical Cancer
    • 1.7.3 Tissue Factor-High Expressing Solid Tumors
    • 1.7.4 Antibody-Drug Conjugate (ADC) Cancer Therapy
    • 1.7.5 Others
  • 1.8 Global Tisotumab Vedotin Market Size & Forecast
    • 1.8.1 Global Tisotumab Vedotin Consumption Value (2021 & 2025 & 2032)
    • 1.8.2 Global Tisotumab Vedotin Sales Quantity (2021-2032)
    • 1.8.3 Global Tisotumab Vedotin Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Genmab A/S
    • 2.1.1 Genmab A/S Details
    • 2.1.2 Genmab A/S Major Business
    • 2.1.3 Genmab A/S Tisotumab Vedotin Product and Services
    • 2.1.4 Genmab A/S Tisotumab Vedotin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Genmab A/S Recent Developments/Updates
  • 2.2 Seagen
    • 2.2.1 Seagen Details
    • 2.2.2 Seagen Major Business
    • 2.2.3 Seagen Tisotumab Vedotin Product and Services
    • 2.2.4 Seagen Tisotumab Vedotin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Seagen Recent Developments/Updates
  • 2.3 Pfizer
    • 2.3.1 Pfizer Details
    • 2.3.2 Pfizer Major Business
    • 2.3.3 Pfizer Tisotumab Vedotin Product and Services
    • 2.3.4 Pfizer Tisotumab Vedotin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Pfizer Recent Developments/Updates
  • 2.4 Zai Lab
    • 2.4.1 Zai Lab Details
    • 2.4.2 Zai Lab Major Business
    • 2.4.3 Zai Lab Tisotumab Vedotin Product and Services
    • 2.4.4 Zai Lab Tisotumab Vedotin Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Zai Lab Recent Developments/Updates

3 Competitive Environment: Tisotumab Vedotin by Manufacturer

  • 3.1 Global Tisotumab Vedotin Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Tisotumab Vedotin Revenue by Manufacturer (2021-2026)
  • 3.3 Global Tisotumab Vedotin Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Tisotumab Vedotin by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Tisotumab Vedotin Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Tisotumab Vedotin Manufacturer Market Share in 2025
  • 3.5 Tisotumab Vedotin Market: Overall Company Footprint Analysis
    • 3.5.1 Tisotumab Vedotin Market: Region Footprint
    • 3.5.2 Tisotumab Vedotin Market: Company Product Type Footprint
    • 3.5.3 Tisotumab Vedotin Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Tisotumab Vedotin Market Size by Region
    • 4.1.1 Global Tisotumab Vedotin Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Tisotumab Vedotin Consumption Value by Region (2021-2032)
    • 4.1.3 Global Tisotumab Vedotin Average Price by Region (2021-2032)
  • 4.2 North America Tisotumab Vedotin Consumption Value (2021-2032)
  • 4.3 Europe Tisotumab Vedotin Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Tisotumab Vedotin Consumption Value (2021-2032)
  • 4.5 South America Tisotumab Vedotin Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Tisotumab Vedotin Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Tisotumab Vedotin Sales Quantity by Type (2021-2032)
  • 5.2 Global Tisotumab Vedotin Consumption Value by Type (2021-2032)
  • 5.3 Global Tisotumab Vedotin Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Tisotumab Vedotin Sales Quantity by Application (2021-2032)
  • 6.2 Global Tisotumab Vedotin Consumption Value by Application (2021-2032)
  • 6.3 Global Tisotumab Vedotin Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Tisotumab Vedotin Sales Quantity by Type (2021-2032)
  • 7.2 North America Tisotumab Vedotin Sales Quantity by Application (2021-2032)
  • 7.3 North America Tisotumab Vedotin Market Size by Country
    • 7.3.1 North America Tisotumab Vedotin Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Tisotumab Vedotin Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Tisotumab Vedotin Sales Quantity by Type (2021-2032)
  • 8.2 Europe Tisotumab Vedotin Sales Quantity by Application (2021-2032)
  • 8.3 Europe Tisotumab Vedotin Market Size by Country
    • 8.3.1 Europe Tisotumab Vedotin Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Tisotumab Vedotin Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Tisotumab Vedotin Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Tisotumab Vedotin Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Tisotumab Vedotin Market Size by Region
    • 9.3.1 Asia-Pacific Tisotumab Vedotin Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Tisotumab Vedotin Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Tisotumab Vedotin Sales Quantity by Type (2021-2032)
  • 10.2 South America Tisotumab Vedotin Sales Quantity by Application (2021-2032)
  • 10.3 South America Tisotumab Vedotin Market Size by Country
    • 10.3.1 South America Tisotumab Vedotin Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Tisotumab Vedotin Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Tisotumab Vedotin Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Tisotumab Vedotin Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Tisotumab Vedotin Market Size by Country
    • 11.3.1 Middle East & Africa Tisotumab Vedotin Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Tisotumab Vedotin Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Tisotumab Vedotin Market Drivers
  • 12.2 Tisotumab Vedotin Market Restraints
  • 12.3 Tisotumab Vedotin Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Tisotumab Vedotin and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Tisotumab Vedotin
  • 13.3 Tisotumab Vedotin Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Tisotumab Vedotin Typical Distributors
  • 14.3 Tisotumab Vedotin Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Tisotumab Vedotin market size was valued at US$ 432 million in 2025 and is forecast to a readjusted size of US$ 1429 million by 2032 with a CAGR of 16.7% during review period.
    Tisotumab vedotin is an antibody-drug conjugate (ADC) composed of a monoclonal antibody targeting tissue factor (TF) linked to a microtubule inhibitor payload. It exerts its anti-tumor effects by specifically binding to tissue factor expressed on the surface of tumor cells, followed by internalization into the cell and release of the cytotoxic agent. This process inhibits microtubule polymerization, blocks cell division, and induces tumor cell apoptosis. Tisotumab vedotin is primarily used for the treatment of recurrent or metastatic cervical cancer and other solid tumors. It has significant clinical value in the field of targeted cancer therapy and ADC-based oncology treatment.In 2025, global teprotumumab production reached approximately 700–900 kg
    Tisotumab vedotin, as an antibody-drug conjugate (ADC) targeting tissue factor (TF), holds an important position in the treatment market for recurrent or metastatic cervical cancer. With the persistent global burden of cervical cancer and limited treatment options for advanced-stage patients, the demand for innovative second-line and later-line therapies continues to increase, driving the rapid expansion of the ADC drug market.
    Tisotumab vedotin has been gradually incorporated into treatment guidelines in multiple countries and has achieved commercial uptake in North America and Europe, owing to its unique mechanism of action and demonstrated efficacy in clinical trials. From a competitive landscape perspective, the field is mainly challenged by immune checkpoint inhibitors and other investigational ADCs. However, its efficacy in specific patient populations provides a degree of differentiated competitive advantage.
    Looking ahead, with potential expansion into additional tissue factor–highly expressing solid tumors, exploration of combination therapy strategies, and the overall growth of the ADC market, its market size is expected to continue expanding, maintaining strong development potential in the field of solid tumor targeted therapy.
    This report is a detailed and comprehensive analysis for global Tisotumab Vedotin market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Tisotumab Vedotin market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Tisotumab Vedotin market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Tisotumab Vedotin market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
    Global Tisotumab Vedotin market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Tisotumab Vedotin
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Tisotumab Vedotin market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Genmab A/S, Seagen, Pfizer, Zai Lab, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Tisotumab Vedotin market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Monoclonal Antibodies
    Polyclonal Antibodies
    Market segment by Specification
    40 mg / vial
    20 mg / vial
    Market segment by Sales Channels
    Hospital
    Retail
    Online
    Market segment by Production Technology
    Intravenous Infusion, IV
    Ocular Prophylaxis-related Administration
    Market segment by Application
    R/M Cervical Cancer
    Tissue Factor-High Expressing Solid Tumors
    Antibody-Drug Conjugate (ADC) Cancer Therapy
    Others
    Major players covered
    Genmab A/S
    Seagen
    Pfizer
    Zai Lab
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Tisotumab Vedotin product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Tisotumab Vedotin, with price, sales quantity, revenue, and global market share of Tisotumab Vedotin from 2021 to 2026.
    Chapter 3, the Tisotumab Vedotin competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Tisotumab Vedotin breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Tisotumab Vedotin market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Tisotumab Vedotin.
    Chapter 14 and 15, to describe Tisotumab Vedotin sales channel, distributors, customers, research findings and conclusion.

    Buy now